Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 safety and pharmacokinetics study of CVN293 in healthy volunteers
NL-OMON59821Phase 1Completed
- Sponsor
- Cerevance
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of CVN293, sponsored by Cerevance. Started Aug 2023; status: completed.
02
Drugs
CVN293
Beyond the preview
Go deeper on NL-OMON59821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59821.